GATTI, GIULIANA
 Distribuzione geografica
Continente #
NA - Nord America 1.209
EU - Europa 915
AS - Asia 662
AF - Africa 2
OC - Oceania 2
SA - Sud America 1
Totale 2.791
Nazione #
US - Stati Uniti d'America 1.201
CN - Cina 559
IE - Irlanda 331
UA - Ucraina 150
FI - Finlandia 125
DE - Germania 95
SG - Singapore 78
SE - Svezia 77
IT - Italia 49
GB - Regno Unito 47
BE - Belgio 19
IN - India 10
JP - Giappone 9
CA - Canada 8
FR - Francia 6
CZ - Repubblica Ceca 3
PL - Polonia 3
RU - Federazione Russa 3
AU - Australia 2
KR - Corea 2
LT - Lituania 2
MU - Mauritius 2
NL - Olanda 2
TR - Turchia 2
CH - Svizzera 1
CL - Cile 1
EE - Estonia 1
ES - Italia 1
ID - Indonesia 1
TH - Thailandia 1
Totale 2.791
Città #
Dublin 331
Chandler 278
Jacksonville 201
Nanjing 158
Ann Arbor 82
Beijing 82
Boardman 74
Ashburn 62
Singapore 59
Princeton 52
Lawrence 50
Nanchang 49
Changsha 48
Wilmington 45
Shenyang 39
Hebei 33
Helsinki 33
Jiaxing 31
Tianjin 29
Medford 28
Shanghai 27
Woodbridge 23
Brussels 19
Hangzhou 17
Houston 9
Pavia 9
Tokyo 9
Milan 8
Pune 7
London 6
Toronto 6
Verona 6
Dallas 5
Fairfield 5
Los Angeles 5
Norwalk 5
Taizhou 5
Zhengzhou 5
Chicago 4
Des Moines 4
Guangzhou 4
Piscataway 4
Seattle 4
Berlin 3
Brno 3
Cologno Monzese 3
Palermo 3
Radomsko 3
San Francisco 3
Auburn Hills 2
Bergamo 2
Catania 2
Como 2
Frankfurt am Main 2
Kunming 2
Rome 2
Shijiazhuang 2
Tappahannock 2
Wuhan 2
Bangkok 1
Briga Novarese 1
Carovigno 1
Changchun 1
Chengdu 1
Dearborn 1
Falkenstein 1
Huntington 1
Ipswich 1
Kilis 1
Livorno 1
Markham 1
Melbourne 1
Munich 1
Nanyang 1
New Delhi 1
Ningbo 1
Ottawa 1
Rowville 1
Shenzhen 1
Stanton 1
Tallinn 1
Voghera 1
Walnut 1
Wenzhou 1
Zurich 1
Totale 2.024
Nome #
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbamazepine in healthy women 100
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. 88
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. 83
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. 81
A simple and rapid HPLC-UV method for the determination of retigabine in human plasma 78
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine sources of variability and preliminary observations on relations with clinical response. 75
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma 75
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. 72
A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers 72
Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 70
Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. 67
The new antiepileptic drugs: Pharmacological and clinical aspects. 66
Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers 65
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. 64
Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response 63
Farmacocinetica delle benzodiazepine. 63
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 62
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.SOPHIE Study Group. 60
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography 60
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. 59
Clinical pharmacokinetics of fluvoxamine. 59
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. 58
Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. 58
The disposition of theophylline in patients with lung and breast cancer. 58
Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. 57
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy 57
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. 57
A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. 56
A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy 55
Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers. 55
CYP2D6-related oxidation polymorphism in Italy 55
The Influence of Dosage, Age, and Comedication on Steady State Plasma Lamotrigine Concentrations in Epileptic Children 52
Protective effect of cyanidin (IdB 1027) against aspirin-induced fall in gastric transmucosal potential difference in normal subjects. 51
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. 51
Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. 49
DIFFERENTIAL-EFFECTS OF VALPROIC ACID AND ENZYME-INDUCING ANTICONVULSANTS ON NIMODIPINE PHARMACOKINETICS IN EPILEPTIC PATIENTS 49
Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. 48
Challenges in the pharmacotherapy of the epilepsies 48
Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. 47
The Influence of Ethnic Factors and Gender on CYP1A2-Mediated Drug Disposition: A Comparative Study in Caucasian and Chinese Subjects Using Phenacetin as a Marker Substrate 43
Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy 41
Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial 40
Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. 39
Reduced Plasma Nisoldipine Concentrations in Phenytoin-Treated Patients with Epilepsy 39
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy 37
Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers 35
The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. 35
The disposition of primidone in elderly patients. 32
Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy 29
Possible enhancement of the first-pass metabolism of prenacetin by grape juice in Chinese subjects 25
Totale 2.838
Categoria #
all - tutte 11.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.752


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020199 0 0 0 0 0 30 5 34 5 68 48 9
2020/2021318 32 27 13 28 1 39 5 51 13 50 40 19
2021/2022210 10 2 4 7 2 6 5 12 13 8 37 104
2022/2023849 91 74 7 53 76 81 0 57 374 4 19 13
2023/2024247 46 40 5 19 25 50 4 23 3 7 12 13
2024/2025202 34 60 17 26 7 58 0 0 0 0 0 0
Totale 2.838